Publications by authors named "J Tarabeia"
Background: While effective preventive measures reduce hospital-acquired infections (HAIs) and the spread of multi-drug resistant organisms (MDROs), studies on the impact of the COVID-19 pandemic and its associated preventive measures remain inconclusive.
Objective: To assess the impact of COVID-19 on HAIs and MDROs and to compare it with the effect of seasonal influenza.
Methods: A retrospective cohort study analyzed prospectively collected data from a tertiary hospital in Haifa, northern Israel, from 2016 to 2021.
Background: Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs).
Methods: We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel.
Article Synopsis
- Rapid and efficient infection control is essential during outbreaks of carbapenem-resistant Enterobacterales, with FTIR spectroscopy emerging as a promising alternative to the costly and complex WGS.
- A study investigated an outbreak of OXA-48-producing E. coli by using FTIR to determine the relatedness of isolates in real-time and confirmed findings with WGS.
- Results showed that FTIR successfully identified the outbreak cluster's genetic similarities and differences among isolates, suggesting its value as a quick, reliable tool for real-time outbreak investigations.
Introduction: The fourth SARS-CoV-2 vaccine dose was found to protect against infection and more importantly against severe disease and death. It was also shown that the risk of symptomatic or severe disease was related to the antibody levels after vaccination or infection, with lower protection against the BA.4 BA.
View Article and Find Full Text PDFThis study assessed humoral response to the third BNT162b2 dose among healthcare workers (HCW). This prospective cohort study of HCW tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) at 1, 3, 6, 9, and 12 months after receiving the second BNT162b2 vaccine dose (tests 1, 2, 3, 4, and 5, respectively). A third (booster) vaccination dose was introduced before test 4.
View Article and Find Full Text PDF